I liked the part about it not being too early to approach potential commercial partners (around 49:30 in the Q&A) when answering a question about things to look forward to in the next 3-6 months. There was also some discussion about the partnership with PyschoGenics in the US as well, and importantly, how they have worked with BP over there to commercialise products. And also important, whilst this was to discuss MDMA inspired therapy, they did drop in the well advanced human trials for cannabinoid treatments, which to me is where EMD has an advantage to become self sustaining by getting a product on shelves to generate revenue streams whilst developing further products without the constant need for CR's.
Should be a good 6-12 months ahead for shareholders, despite the market jitters.
- Forums
- ASX - By Stock
- EMD
- Ann: MDMA-inspired drug discovery presentation
Ann: MDMA-inspired drug discovery presentation, page-6
Featured News
Add EMD (ASX) to my watchlist
|
|||||
Last
3.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.72M |
Open | High | Low | Value | Volume |
3.6¢ | 3.6¢ | 3.6¢ | $1.987K | 55.20K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 486341 | 3.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.6¢ | 834419 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 486341 | 0.035 |
3 | 533841 | 0.034 |
3 | 23378 | 0.033 |
2 | 107500 | 0.032 |
1 | 32258 | 0.031 |
Price($) | Vol. | No. |
---|---|---|
0.036 | 834419 | 1 |
0.037 | 70000 | 1 |
0.039 | 190000 | 2 |
0.040 | 57647 | 1 |
0.041 | 38238 | 2 |
Last trade - 11.47am 15/08/2024 (20 minute delay) ? |
Featured News
EMD (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online